Biogen Inc
BIIB
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 29, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
110% upsideUndervalued by 110% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $28.84 Billion |
|---|---|
| Enterprise Value | $32.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.85 |
| Beta | 0.2 |
| Outstanding Shares | 147,200,000 |
Return
| Return on Equity | 7.36% |
|---|---|
| Return on Assets | 4.65% |
| Return on Invested Capital | 3.46% |
Valuation & Multiples
| P/E Ratio | 20.95 |
|---|---|
| PEG | 63.78 |
| Price to Sales | 2.9 |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | 3.23 |
| Enterprise Value to EBIT | 35 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.36 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3333▲ 68.76% |
|---|---|
| Total Calls | 1,294,349▼ 62.94% |
| Total Puts | 1,725,764▼ 23.47% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 91.53%▼ 3.77% |
|---|---|
| Total Invested | $24.61B▲ 0.11% |
| Investors Holding | 1,044▼ 6.00% |
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...
Relevant Senate Committees
This committee provides crucial analysis and revenue estimates for all tax legislation. Its technical expertise and reports directly influence corporate tax structures, capital investment credits, and the overall tax burden on industries like biotechnology, fundamentally impacting Biogen's financial planning and profitability.
This powerful committee controls taxation, trade, and entitlement spending (Medicare/Medicaid). Decisions on corporate tax policy directly impact Biogen's profitability, and policies related to Medicare pricing for drugs are critically important for its revenue streams and market access.
This committee directly regulates the FDA, which is the primary body for drug approval, a critical process for Biogen. Its oversight of the NIH also influences the broader research ecosystem that Biogen operates within, directly impacting its pipeline and market opportunities.
This committee's oversight of intellectual property (patents) is critical for pharmaceutical and biotech companies like Biogen, protecting their R&D investments. Its role in antitrust enforcement can also significantly influence mergers, acquisitions, and competitive practices within the industry.